Latest Articles
XBP1 promotes endometrial fibrosis through cGAS-STING signaling pathway in intrauterine adhesion - Nature
XBP1 promotes endometrial fibrosis through cGAS-STING signaling pathway in intrauterine adhesion Nature
Published: July 2, 2025, 5:48 a.m.
XBP1 promotes endometrial fibrosis through cGAS-STING signaling pathway in intrauterine adhesion - nature.com
XBP1 promotes endometrial fibrosis through cGAS-STING signaling pathway in intrauterine adhesion nature.com
Published: July 2, 2025, 5:48 a.m.
UFE Doesn’t Remove Fibroids–Here’s What Women Aren’t Being Told - The Malaysian Reserve
UFE Doesn’t Remove Fibroids–Here’s What Women Aren’t Being Told The Malaysian Reserve
Published: June 26, 2025, 10:51 a.m.
UFE Doesn't Remove Fibroids--Here's What Women Aren't Being Told - StreetInsider
UFE Doesn't Remove Fibroids--Here's What Women Aren't Being Told StreetInsider
Published: June 25, 2025, 10:14 a.m.
UFE Doesn't Remove Fibroids—Here's What Women Aren't Being Told - Morningstar
UFE Doesn't Remove Fibroids—Here's What Women Aren't Being Told Morningstar
Published: June 25, 2025, 10 a.m.
Matrix Tropism Influences Endometriotic Cell Attachment Patterns.
The initiation of endometriotic lesions is not well understood or characterized because endometriosis is typically diagnosed at an advanced stage. Endometriotic lesions are most often found on pelvic tissues and …
Published: June 23, 2025, midnight
The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 - BMC Public Health
The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 BMC Public Health
Published: May 14, 2025, 5:32 a.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - BioSpace
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids BioSpace
Published: May 7, 2025, 1:28 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - The Manila Times
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids The Manila Times
Published: May 7, 2025, 12:24 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - PR Newswire
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids PR Newswire
Published: May 7, 2025, noon
Link copied to clipboard!